Skip to main content

AtriCure, Inc.

corporate_fare Company Profile

AtriCure, Inc.

ATRC·NASDAQ·Industrial Applications And Services·CIK 0001323885

We are a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Afib is an irregular heartbeat affecting over 59 million people worldwide. Our cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. In open-heart procedures, our products are used alongside other heart surgeries like mitral or aortic valve repair or coronary artery bypass. Minimally invasive procedures are performed independently and often combine surgical procedures using our ablation and LAAM products with catheter ablation. Our pain management solutions are used by physicians to freeze nerves during cardiac, thoracic, or amputation surgical procedures. These solutions include our cryoICE cryoSPHERE ® and cryoXT™ probes for pain management, known as Cryo Nerve Block. These products provide temporary relief of post-operative pain, allowing healing while nerves regenerate.

AtriCure, Inc. (NASDAQ:ATRC) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors ATRC SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Shareholders Approve 2.25 Million New Shares for Equity Incentive and ESPP
  • AtriCure Amends Q1 Report to Add Full-Year 2026 Profitability Guidance
  • AtriCure Issues 2026 Revenue Guidance of $600M-$610M
  • AtriCure Reports Strong Q1 2026 Results with 14.3% Revenue Growth and Shift to Profitability
  • AtriCure Seeks Shareholder Approval for Significant Equity Plan Expansions, Potentially Authorizing Over 18% Dilution

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$534.53M
Net Income
-$11.45M
Diluted EPS
-$0.24
Op. Cash Flow
$57.33M
Free Cash Flow
$48.28M
Gross Profit
$400.78M
Operating Income
-$9.45M
Cash & Equivalents
$167.43M
Total Debt
$61.87M
Debt / Equity
0.13×
Net Margin
-2.1%
Shares Outstanding
49.79M sh
Source: 10-K · filed 2026-02-19 · accession 0001323885-26-000007
Browse all tickers starting with A →
$28.79
52-week range · as of 2026-05-19 $25.52 – $43.18
Market cap
$1.46B
Volume
700.9K (0.8× avg)
3-mo avg 856.3K
Live data · 2026-06-14 05:28 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ATRC - Latest Insights

ATRC
May 19, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.80
Real-time Price: $28.79 info
Change: -$0.010 (-0.03%) info
Market Cap: $1.458B info
ATRC
May 05, 2026, 9:01 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $30.40
Real-time Price: $28.79 info
Change: -$1.61 (-5%) info
Market Cap: $1.458B info
ATRC
May 05, 2026, 4:23 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $29.50
Real-time Price: $28.79 info
Change: -$0.710 (-2%) info
Market Cap: $1.458B info
ATRC
May 05, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.39
Real-time Price: $28.79 info
Change: -$0.600 (-2%) info
Market Cap: $1.458B info
ATRC
Apr 06, 2026, 11:54 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $29.33
Real-time Price: $28.79 info
Change: -$0.540 (-2%) info
Market Cap: $1.458B info
ATRC
Feb 19, 2026, 12:39 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $32.39
Real-time Price: $28.79 info
Change: -$3.59 (-11%) info
Market Cap: $1.458B info
ATRC
Feb 17, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $32.97
Real-time Price: $28.79 info
Change: -$4.18 (-13%) info
Market Cap: $1.458B info
ATRC
Jan 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $41.46
Real-time Price: $28.79 info
Change: -$12.67 (-31%) info
Market Cap: $1.458B info